| Full text | |
| Author(s): Show less - |
Borba, Eduardo F.
[1]
;
Saad, Carla G. S.
[1]
;
Pasoto, Sandra G.
[1]
;
Calich, Ana L. G.
[1]
;
Aikawa, Nadia E.
[1, 2]
;
Ribeiro, Ana C. M.
[1]
;
Moraes, Julio C. B.
[1]
;
Leon, Elaine P.
[1]
;
Costa, Luciana P.
[1]
;
Guedes, Lissiane K. N.
[1]
;
Silva, Clovis A. A.
[1, 2]
;
Goncalves, Celio R.
[1]
;
Fuller, Ricardo
[1]
;
Oliveira, Suzimara A.
[3]
;
Ishida, Maria A.
[4]
;
Precioso, Alexander R.
[5]
;
Bonfa, Eloisa
[1]
Total Authors: 17
|
| Affiliation: | [1] Univ Sao Paulo, Fac Med, Div Rheumatol, BR-05403010 Sao Paulo - Brazil
[2] Univ Sao Paulo, Fac Med, Paediat Rheumatol Unit, BR-05403010 Sao Paulo - Brazil
[3] Univ Sao Paulo, Fac Med, Dept Pathol, BR-05403010 Sao Paulo - Brazil
[4] Univ Sao Paulo, Fac Med, Adolfo Lutz Inst, BR-05403010 Sao Paulo - Brazil
[5] Butantan Inst, Sao Paulo - Brazil
Total Affiliations: 5
|
| Document type: | Journal article |
| Source: | RHEUMATOLOGY; v. 51, n. 6, p. 1061-1069, JUN 2012. |
| Web of Science Citations: | 24 |
| Abstract | |
Objective. To assess the efficacy and safety of pandemic 2009 influenza A (H1N1) in SLE under different therapeutic regimens. Methods. A total of 555 SLE patients and 170 healthy controls were vaccinated with a single dose of a non-adjuvanted preparation. According to current therapy, patients were initially classified as SLE No Therapy (n = 75) and SLE with Therapy (n = 480). Subsequent evaluations included groups under monotherapy: chloroquine (CQ) (n = 105), prednisone (PRED) epsilon 20 mg (n = 76), immunosuppressor (IS) (n = 95) and those with a combination of these drugs. Anti-H1N1 titres and seroconversion (SC) rate were evaluated at entry and 21 days post-vaccination. Results. The SLE with Therapy group had lower SC compared with healthy controls (59.0 vs 80.0%; P < 0.0001), whereas the SLE No Therapy group had equivalent SC (72 vs 80.0%; P = 0.18) compared with healthy controls. Further comparison revealed that the SC of SLE No Therapy (72%) was similar to the CQ group (69.5%; P = 0.75), but it was significantly reduced in PRED epsilon 20 mg (53.9%; P = 0.028), IS (55.7%; P = 0.035) and PRED epsilon 20 mg + IS (45.4%; P = 0.038). The concomitant use of CQ in each of these later regimens was associated with SC responses comparable with SLE No Therapy group (72%): PRED epsilon 20 mg + CQ (71.4%; P = 1.00), IS + CQ (65.2%; P = 0.54) and PRED epsilon 20 mg + IS + CQ (57.4%; P = 0.09). Conclusion. Pandemic influenza A H1N1/2009 vaccine response is diminished in SLE under immunosuppressive therapy and antimalarials seems to restore this immunogenicity. (AU) | |
| FAPESP's process: | 10/10749-0 - Anti-influenza H1N1/2009 vaccine in autoimmune rheumatic diseases patients |
| Grantee: | Eloisa Silva Dutra de Oliveira Bonfá |
| Support Opportunities: | Regular Research Grants |